Company Overview
| Stock Name | Conant Optical |
|---|---|
| Stock Code | 02276 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們為中國領先的樹脂眼鏡鏡片製造商,於往績記錄期在超過80個國家進行銷售,產品包括標準化鏡片及定製鏡片,涵蓋不同折射率及功能。按2020年樹脂眼鏡鏡片產量計算,我們在中國樹脂鏡片製造商中排名第一。 |
| Listing Date | 2021-12-16 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國(上海)自由貿易試驗區臨港新片區宏祥北路83弄1-42號36幢1層 |
| Business Address (Hong Kong) | 香港灣仔皇后大道東248號大新金融中心40樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.conantoptical.com.cn |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 4.46 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 2,230 |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2021-11-30 to 2021-12-09 |
| Global Offering Shares | 121,600,000 shares |
| HK Public Offer Shares (Initial) | 12,160,000 shares (10.0%) |
| Public Offer Lots (Initial) | 24,320lots (Pool A12,160lots,Pool B12,160lots) |
| International Placing Shares (Initial) | 109,440,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 426,600,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 542,336,000 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 2,230 |
| 2 lots | 1,000 | HK$ 4,460 |
| 3 lots | 1,500 | HK$ 6,690 |
| 4 lots | 2,000 | HK$ 8,920 |
| 5 lots | 2,500 | HK$ 11,150 |
| 6 lots | 3,000 | HK$ 13,380 |
| 7 lots | 3,500 | HK$ 15,610 |
| 8 lots | 4,000 | HK$ 17,840 |
| 10 lots | 5,000 | HK$ 22,300 |
| 12 lots | 6,000 | HK$ 26,760 |
| 14 lots | 7,000 | HK$ 31,220 |
| 16 lots | 8,000 | HK$ 35,680 |
| 18 lots | 9,000 | HK$ 40,140 |
| 20 lots | 10,000 | HK$ 44,600 |
| 40 lots | 20,000 | HK$ 89,200 |
| 60 lots | 30,000 | HK$ 133,800 |
| 80 lots | 40,000 | HK$ 178,400 |
| 100 lots | 50,000 | HK$ 223,000 |
| 120 lots | 60,000 | HK$ 267,600 |
| 140 lots | 70,000 | HK$ 312,200 |
| 160 lots | 80,000 | HK$ 356,800 |
| 180 lots | 90,000 | HK$ 401,400 |
| 200 lots | 100,000 | HK$ 446,000 |
| 300 lots | 150,000 | HK$ 669,000 |
| 400 lots | 200,000 | HK$ 892,000 |
| 500 lots | 250,000 | HK$ 1,115,000 |
| 600 lots | 300,000 | HK$ 1,338,000 |
| 800 lots | 400,000 | HK$ 1,784,000 |
| 1,800 lots | 900,000 | HK$ 4,014,000 |
| 2,000 lots | 1,000,000 | HK$ 4,460,000 |
Stock Connect Inclusion Analysis
| Avg Daily HK Mkt Cap | HK$ 21.62B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 1,902,636,000 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利约人民币128.5百万元 |
| Period-End Cash Balance | 人民幣201.9百萬元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2018 | 2019 | 2020 |
|---|---|---|---|
| Revenue | 853,760 | 1,058,846 | 1,093,164 |
| Cost of sales | -592,419 | -708,968 | -711,113 |
| Gross profit | 261,341 | 349,878 | 382,051 |
| Other income and gains, net | 19,471 | 20,592 | 22,898 |
| Selling and distribution expenses | -62,867 | -75,305 | -67,101 |
| Administrative expenses | -98,719 | -107,930 | -112,287 |
| Operating profit | 102,409 | 186,915 | 202,384 |
| Net finance costs | -9,448 | -47,447 | -47,079 |
| Share of associates and JVs | 0 | -152 | -42 |
| Profit before tax | 92,961 | 139,316 | 155,263 |
| Income tax expense | -14,499 | -27,415 | -26,801 |
| Profit for the year | 78,462 | 111,901 | 128,462 |
| Profit attributable to owners | 78,462 | 111,901 | 128,462 |
Balance Sheet
| Item | 2018 | 2019 | 2020 |
|---|---|---|---|
| Cash and cash equivalents | 109,182 | 62,118 | 201,850 |
| Trade and bills receivables | 149,867 | 209,110 | 231,007 |
| Inventories | 286,254 | 332,686 | 391,362 |
| Total current assets | 656,604 | 959,798 | 1,025,324 |
| Total assets | 1,082,674 | 1,374,654 | 1,444,200 |
| Total current liabilities | 780,116 | 530,552 | 521,879 |
| Total liabilities | 969,516 | 996,456 | 939,666 |
| Total equity | 113,158 | 378,198 | 504,534 |
| Equity attributable to owners | 113,158 | 378,198 | 504,534 |
Income Statement
Balance Sheet
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 4.55 |
|---|---|
| First Day Open | HK$ 4.43 |
| First Day Change | 2.02% |
| First Day Volume | 9628500.0 |
| First Day Turnover | 43181100.0 |
| Use of Proceeds | 1、約46.4%或219.7百萬港元將用于提高上海生產基地及江蘇生產基地的產能;
2、約19.9%或94.2百萬港元將用于加強我們的研發實力;
3、約10.3%或48.8百萬港元將用于加大我們的銷售及營銷力度;
4、約10.0%或47.3百萬港元將用作營運資金及一般企業用途;
5、約8.1%或38.4百萬港元將用于提升生產效率及工藝的技術。
6、約5.3%或25.1百萬港元將用于償還以下銀行借款未償還款項,該等借款主要用于撥付營運資金以支持業務運作。 |
Underwriting Syndicate
Sole Sponsor (1)
国泰君安融资有限公司 CE AGS488
Overall Coordinators (1)
国泰君安证券(香港)有限公司 CE ABY236
Joint Bookrunners (1)
国泰君安证券(香港)有限公司 CE ABY236
Joint Lead Managers (4)
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 費錚翔 | — |
| Company Secretary | 王承鏱、曹雪 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 費錚翔先生為控股股東,持有212,740,030股經轉換H股,佔緊隨全球發售完成後已發行股本總額約49.87%;其配偶申洲波被視為持有相同權益。 |
|---|




